WO2019203813A1 - Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene - Google Patents
Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene Download PDFInfo
- Publication number
- WO2019203813A1 WO2019203813A1 PCT/US2018/028077 US2018028077W WO2019203813A1 WO 2019203813 A1 WO2019203813 A1 WO 2019203813A1 US 2018028077 W US2018028077 W US 2018028077W WO 2019203813 A1 WO2019203813 A1 WO 2019203813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablets
- candies
- gingivitis
- lotions
- ointments
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000036541 health Effects 0.000 title claims abstract description 18
- 230000006872 improvement Effects 0.000 title claims abstract description 9
- 208000007565 gingivitis Diseases 0.000 claims abstract description 33
- 208000020670 canker sore Diseases 0.000 claims abstract description 27
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 17
- 239000000499 gel Substances 0.000 claims description 16
- 239000002324 mouth wash Substances 0.000 claims description 14
- 229940051866 mouthwash Drugs 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 235000009508 confectionery Nutrition 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 13
- 239000006210 lotion Substances 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 13
- 229940034610 toothpaste Drugs 0.000 claims description 13
- 239000000606 toothpaste Substances 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- -1 gummies Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 239000006188 syrup Substances 0.000 claims description 12
- 235000020357 syrup Nutrition 0.000 claims description 12
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 208000023409 throat pain Diseases 0.000 claims description 8
- 231100000397 ulcer Toxicity 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000000740 bleeding effect Effects 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 231100000862 numbness Toxicity 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 230000001055 chewing effect Effects 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000009747 swallowing Effects 0.000 claims description 3
- 206010006784 Burning sensation Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 description 13
- 208000002399 aphthous stomatitis Diseases 0.000 description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 239000007910 chewable tablet Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- KTRRXJQAOOYSDA-UHFFFAOYSA-N 1,7-bis(4-hydroxyphenyl)heptane-3,5-dione Chemical compound C1=CC(O)=CC=C1CCC(=O)CC(=O)CCC1=CC=C(O)C=C1 KTRRXJQAOOYSDA-UHFFFAOYSA-N 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to a novel composition containing tetrahydroeurcuminoids for die improvement of oral health and hygiene. More specifically, the invention relates to a novel tetrahydrocurcuminoid composition and its application in therapeutic management of canker sore mid gingivitis.
- the health and hygiene of the teeth, the mouth, and mucosal tracts of the oral cavity is important to a person's overall health-
- the common type of oral disease include dental cavities, caries, bad breath and gum diseases, including canker sore, gingivitis, and periodontitis.
- RAS Recurrent aphthous stomatitis
- canker sores is one of the most common, painful oral ailments, characterized by multiple, small, round, or ovoid ulcers with circumscribed margins, erythematous haloes, and yellow or grey floors that presents itself in childhood or adolescence.
- Scully C Porter S. Oral mucosal disease: recurrent aphthous stomatitis, Br J Oral Maxillofac Surg. 2008 Apr;46(3): 198-206; Preeti L, et al., Recurrent aphthous stomatitis, J Oral Maxillofac
- Gingivitis affects an estimated 80% of the population and is the world's most predominant inflammatory periodontal disease. The disease is initiated with a pathogenic biofilm, or plaque, around the teeth followed by a host immune-inflammatory response that advances the disease.
- the principle objective of the invention is to disclose a composition containing tetrahydrocurcuminoids and for the improvement of oral health and hygiene.
- the present invention discloses a composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene. Specifically the invention discloses a novel composition of tetrahydrocurcuminoids for the therapeutic management of canker sore and gingivitis.
- Fig,la shows graphical representation of median VAS seme at three time points; p value ⁇ 0.001 using Friedman ANNOV A,
- Fig, lb shows graphical representation of median throat relief score at three points
- Fig. lc shows graphical representation of distribution of patients as per throat numbness at different time points
- Fig. 2a and 2b shows Line plots mean values of different LOE & SILNESS Index parameters ami total points at three times in Gingivitis group
- the invention relates to a novel composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene.
- the composition contains tetrahydrocurcumin, teirahydrodemethoxycurcumin, tetrahydrobis-demethoxycurcumin, octahydrocurcuminoids and hexahydrocurcuminoids.
- the composition is formulated with pharmaceutically, nutraceuticaily and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
- the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables are available separately or together in an oral health kit containing the said forms.
- the present invention discloses a method for therapeutic management of canker sore in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with canker sore.
- the symptoms of canker sore include, but not limited to. throat pain, ulcer, lesion, throat numbness, sore throat, bleeding, swelling at the site, reddening at the site, inflammation at the site, burning, swelling and paid in lymph node, difficulty in chewing and difficulty in swallowing.
- the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents of carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables hi a related embodiment, the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables, are available separately or together in an oral health kit containing the said forms.
- the mammal is preferably human.
- the present invention discloses a method for therapeutic management of gingivitis in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with gingivitis.
- the symptoms of gingivitis include, but not limited to, taste acceptability, burning sensation, dryness, soreness, ulcer, staining of teeth and tongue, and allergy.
- the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
- the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables are available separately or together in an oral health kit containing the said forms.
- the mammal is preferably human. [Para0017] Specific illustrative examples enunciating the most preferred embodiments are included herein below.
- the sample size of the study was 60, with 30 subjects assigned to each of die two study arms in a manner there would be 30 subjects with canker sore and throat pain and 30 subjects with gingivitis. However, 31 subjects were enrolled for Canker Sore and 29 were enrolled for
- [ParaOQ32] AU enrolled subjects were instructed to self administer one chewable tablet (oral dosing) twice daily containing lOOmg of tetrahydrocurcuminoids for a period of 21 days.
- Table 1 Distribution of patients with different no of lesions across study visits.
- Example 3 Compositions / formulations containing tetrahydrocurcuminoids
- Tables 4-9 provide illustrative examples of nutraceutical formulations containing tetrahydrocurcuminoids for the management of canker sore and gingivitis [Para0059] Table 4: Tetrahydrocurcuminoids Chewable Tablet
- Table 10 and 11 provides illustrative examples for a mouth gel and mouth wash formulation containing tetrahydrocurcuminoids for the management of canker sore and gingivitis
- the invention also provides an illustrative example of an oral health kit comprising of formulation containing tetrahydracurcuminoids which include, but not limited to, the following: 1. Chewable tablets, candies and guinmies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a novel composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene. More specifically, disclosed is a novel composition of tetrahydrocurcuminoids and its application in the therapeutic management of canker sore and gingivitis.
Description
COMPOSITIONS CONTAINING TETRAHYDROCURCUMINOIDS FOR
IMPROVEMENT OF ORAL HEALTH AND HYGIENE
FIELD OF THE INVENTION
[ParaOOOl] The present invention relates to a novel composition containing tetrahydroeurcuminoids for die improvement of oral health and hygiene. More specifically, the invention relates to a novel tetrahydrocurcuminoid composition and its application in therapeutic management of canker sore mid gingivitis.
BACKGROUND OF THE INVENTION
[ParaOOOl] DESCRIPTION OF PRIOR ART
[ParaOO03] The health and hygiene of the teeth, the mouth, and mucosal tracts of the oral cavity is important to a person's overall health- The common type of oral disease include dental cavities, caries, bad breath and gum diseases, including canker sore, gingivitis, and periodontitis.
Canker sores and gingivitis are the most commonly occurring oral problems. Recurrent aphthous stomatitis (RAS) (aphthae; canker sores) is one of the most common, painful oral ailments, characterized by multiple, small, round, or ovoid ulcers with circumscribed margins, erythematous haloes, and yellow or grey floors that presents itself in childhood or adolescence. (Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis, Br J Oral Maxillofac Surg. 2008 Apr;46(3): 198-206; Preeti L, et al., Recurrent aphthous stomatitis, J Oral Maxillofac
Pathol,. 2011; 15:252-6). Gingivitis affects an estimated 80% of the population and is the world's most predominant inflammatory periodontal disease. The disease is initiated with a
pathogenic biofilm, or plaque, around the teeth followed by a host immune-inflammatory response that advances the disease.
[Para004] As a main stay to maintain oral hygiene, mechanical plaque control measures are generally employed. But, these techniques are either time consuming or require motivation and skill to be performed well for effective relief against the symptoms. Hence, antimicrobial agents such as chlorhexidine, metronidazole etc are being used extensively as an adjunct to mechanical cleaning. However, these artificial drugs have unpleasant side-effects and hence a safe and effective natural/herbal source in providing relief against oral health problems is the current industrial requirement.
[ParaOOS] Turmeric, especially curcumin is an effective natural alternative for the management of oral health problems which is specifically documented in the following :
1. Clinical efficacy of turmeric use in gingivitis: A comprehensive review, Stoyell KA,
Mappus JL, Gandhi MA, Complement Ther Clin Pract. 2016 Nov; 25: 13-17).
2. Efficacy of curcumin in the treatment of chronic gingivitis: a pilot study. Muglikar, S.,
Patil, K.C., Shivswami, S., and Hegde, R., Oral Health and Preventive Dentistry. 2012;
I l(l):81-86)
3. Comparison of effectiveness of curcumin with triamcinolone acetonide in the gel form in treatment of minor recurrent aphthous stomatitis: A randomized clinical trial, Deshmukh
RA, Bagewadi AS, Iht J Pharm Investig. 2014 Jul;4(3): 138-41).
4. Oral care compositions, Brading et al., US patent no. 8916139
[Para006] Owing to the problems associated with curcumin when incorporated in oral care compositions like bioavailability, degradation, discoloration, there is a need to develop a stable natural alternative for management of oral health and hygiene, especially for canker sore and gingivitis because of their different pathological features. The invention solves the above problem by disclosing a composition containing tetrahydrocurcuminoids for the therapeutic management of canker sore and gingivitis.
[Para007] The principle objective of the invention is to disclose a composition containing tetrahydrocurcuminoids and for the improvement of oral health and hygiene.
[Para008] It is another objective of the invention to disclose a composition containing tetrahydrocurcuminoids for therapeutic management of canker sore and gingivitis.
SUMMARY OF THE INVENTION
[Para009] The present invention discloses a composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene. Specifically the invention discloses a novel composition of tetrahydrocurcuminoids for the therapeutic management of canker sore and gingivitis.
BRIEF DESCRIPTION OF THE FIGURES (Fig.la, lb, lc, 2a and 2b)
[ParaOOlO] Fig,la shows graphical representation of median VAS seme at three time points; p value < 0.001 using Friedman ANNOV A,
[Para0011] Fig, lb shows graphical representation of median throat relief score at three points
[Para0012] Fig. lc shows graphical representation of distribution of patients as per throat numbness at different time points
[Para0013] Fig. 2a and 2b shows Line plots mean values of different LOE & SILNESS Index parameters ami total points at three times in Gingivitis group
DESCRIPTION OF MOST PREFEERED EMBODIMENTS
[ParaOOH] hi a most preferred embodiment, the invention relates to a novel composition containing tetrahydrocurcuminoids for the improvement of oral health and hygiene. In a related embodiment the composition contains tetrahydrocurcumin, teirahydrodemethoxycurcumin, tetrahydrobis-demethoxycurcumin, octahydrocurcuminoids and hexahydrocurcuminoids. In a related embodiment the composition is formulated with pharmaceutically, nutraceuticaily and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables. In a related embodiment, the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables, are available separately or together in an oral health kit containing the said forms.
[ParaOOlS] In another preferred embodiment, the present invention discloses a method for therapeutic management of canker sore in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with canker sore. In another related embodiment, the symptoms of canker sore include, but not limited to. throat pain, ulcer, lesion, throat numbness, sore throat, bleeding, swelling at the site, reddening at
the site, inflammation at the site, burning, swelling and paid in lymph node, difficulty in chewing and difficulty in swallowing. In a yet another related embodiment the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents of carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables hi a related embodiment, the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables, are available separately or together in an oral health kit containing the said forms. In another embodiment, the mammal is preferably human.
[Para0016] In another preferred embodiment, the present invention discloses a method for therapeutic management of gingivitis in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with gingivitis. In another related embodiment, the symptoms of gingivitis include, but not limited to, taste acceptability, burning sensation, dryness, soreness, ulcer, staining of teeth and tongue, and allergy. In a yet another related embodiment the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables. In a related embodiment, the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables, are available separately or together in an oral health kit containing the said forms. In another embodiment, the mammal is preferably human.
[Para0017] Specific illustrative examples enunciating the most preferred embodiments are included herein below.
[ParaOOlS] EXAMPLES
[Para0019j Example 1: Experimental procedures
[Para0020] Product description
[Para0021] The study supplements were supplied in the form of chewable tablets with oral dosing twice daily containing lOOmg of tetrahydrocurcuminoids.
[Para0022] Ethics and informed consent
[Para0023] This trial was conducted in accordance with the clinical research guidelines established by the Drugs and Cosmetics Act, 1940 of India, Drugs and Cosmetics Rules, 1945 of
India, Ethical Guidelines for Biomedical Research on Human Participants, 2006 of Indian
Council of Medical Research (ICMR) in India, die principles enunciated in the Declaration of
Helsinki, Edinburgh (Anonymous, 2000) and the ICH - harmonized tripartite guideline regarding
Good Clinical Practice (GCP). The study was approved by the Institutional ethics committee, a written informed consent was obtained, and the study was registered at Clinical Trials Registry-
India (www,ctri.nic,in) (Identifier: CTRV2017/01/007670). There were no changes to the methods or planned endpoints after study initiation.
[Para0024j Participants
[Para0025] Subjects were included in the study if indicated“Yes” to all of the inclusion criteria and "No” to all of the exclusion criteria.
[Para0026J Inclusion Criteria:
1. Male and/or female - Healthy, with no systemic disease (diabetes).
2. Age between 18 to 60 years.
3. Patients having mouth ulcers with throat pain or Patients with mild to moderate gingivitis.
4. Patients having erupted teeth.
5. Willing to come for regular follow-up visits.
6. Able to give written informed consent
[Para0027] Exclusion Criteria:
1. Smokers.
2. Presence of any systemic hematological problems.
3. Drug or alcohol abuse.
4. Under systemic or topical corticosteroid therapy.
5. Pregnant women or lactating mothers
6. History of HIV and other vital infections.
7. History of any antibiotic therapy in past 3 months.
8. History of oral prophylaxis within 6 months previous to the study
9. Patients with mouth breathing habit.
10. Patients using orthodontic and prosthodontics appliances
11. Are on analgesics or antiseptics.
12. Patients who have received any periodontal therapy in the past 6 months.
[Para0028] Trial Design
[Para0029] A Prospective, open label, two arm, clinical study to evaluate the efficacy and safety in the treatment of canker sore and gingivitis was conducted in India at two different sites: 1)
Noble Hospital Pvt Ltd., Pune, Maharashtra, India. 2) Sri Venkateshwara Hospital, Bangalore,
India. The sample size of the study was 60, with 30 subjects assigned to each of die two study arms in a manner there would be 30 subjects with canker sore and throat pain and 30 subjects with gingivitis. However, 31 subjects were enrolled for Canker Sore and 29 were enrolled for
Gingivitis after obtaining signed Informed Consent from these subjects. Subjects were non blinded as it was an open label study. Compliance with study supplement was reviewed at each visit. The subjects were allowed to take their regular diet The study consisted of a 21 day intervention period. Subjects visited the study site on screening (day -3 i,e. three days prior to baseline visit), baseline (day 0), visit day 14 and day 21.
[Para0030] Intervention
[Para0031] Male and female subjects between the age group of 18 to 60 years suffering with mouth ulcers along with throat pain were screened for the study. The screening procedures included medical history, medication and treatment history, physical examination, demographics and vital signs, pregnancy test in case of females, laboratory investigation (haematology), and
efficacy assessments were conducted. Comorbtd conditions including any active, chronic, recurrent or latent infections.
[ParaOQ32] AU enrolled subjects were instructed to self administer one chewable tablet (oral dosing) twice daily containing lOOmg of tetrahydrocurcuminoids for a period of 21 days.
[Para0033] Efficacy Outcomes
[Para0034] For Canker sore with throat pain -
• Number of ulcers healed.
• Pain intensity Assessment by VAS (Visual Analogue Scale).
• Ulcer size reduction.
• Duration of complete healing of ulcers.
• Clinical Photographs of the Lesion.
• Throat Numbness Scale.
• Sore Throat Relief Scale.
[Para0035] For Gingivitis -
• Loe and Silness Gingival index.
• Subjective criteria for Gingivitis.
• Objective criteria for Gingivitis.
• Clinical Photographs of gingival region.
[Para0036] Secondary Objective
[Para0037] To assess the safety of tetrahydrocurcuminoids in the treatment of Canker sore with throat pain and gingivitis.
[Para0038] Safety Outcomes:
• Any reports of adverse or serious adverse events.
• Abnormal vital signs & lab parameters.
[Para0039] Statistical Analysis of Efficacy Evaluation
[Para0040] The average scores were calculated separately on a per-subject basis at Baseline and
Day 21. For statistical purpose die Screening scores were considered as Baseline. The Day 21 means for each endpoint were modeled separately with analysis of covariance, using the respective baseline score as a covariate. All treatment comparisons were tested at the two-sided
5% significance level.
[Para0041] Example 2: Results
[Para0O42] This Study was conducted in India across two sites from November 2016 to March
2017. A total of 60 adult patients were enrolled and treated for 21 days with twice a day dosing every morning and evening. A total of 11 women and 49 men participated in die study. Total of
31 patients were enrolled in canker sore, out of which 1 patient dropped out and total 29 patients were enrolled in gingivitis arm. The female to male ratio completing the study was 10:49 with
one female dropout. Patients enrolled were having no other physical abnormalities except either canker sore or gingivitis.
(Para0043) Efficacy outcome
[Para0044] Canker sore
[Para0045] The clinical parameter like systolic and diastolic BP, pulse rate, heart rate, respiratory rate and BMI were compared using repeated measure analysis of variance and was insignificant in between two time points. Physical examination revealed that general appearance, heart, lungs, abdomen, extremities and neurological functions were normal.
[Para0046] There was gradual decrease in numbers of lesion across the study period (Table 1). The duration taken for tetrahydrocurcuminoids to treat canker sore was an average of 21 days as almost all the symptoms were reduced at the final visit There was statistically significant reduction in number of cases with numbness after treatment (Fig. la). Further, comparison of throat relief score before and after treatment showed significant improvement (Fig. lb). Also,
VAS scores before and after treatment has shown significant reduction from median score of 3 to
0 (Fig. lc).
[Para0047] Table 1: Distribution of patients with different no of lesions across study visits.
[Para0048] There was a significant change in the symptoms of canker sore with throat pain like pain at site, burning at site, reddening, difficulty in chewing and swallowing post treatment.
Bleeding was insignificant due to treatment during the study period (Table 2).
[Para0049] Table 2: Comparison of signs and symptoms before and after treatment of canker sore patients
P-value < 0.001 except for bleeding (P > 0.05)
[ParaOOSO] Gingivitis
[ParaOOSl] The clinical parameter like systolic and diastolic BP, pulse rate, heart rate, respiratory rate and BMI were compared using analysis of covariance and was insignificant in between two time points. The general appearance, heart, lungs, abdomen, extremities and neurological functions were shown normal by physical examination.The duration taken by tetrahydrocurcuminoids to treat ginvivitis is in average of 14- 21 days.
[Para0052] Loe & Silness index was compared between two time points. Appearance differed significantly before and after treatment as indicated by P-value of 0.008 using Wilcoxon signed rank test Also, there was significant difference in the bleeding scores between baseline and visit
4 as revealed by P-value of 0.002. Further, inflammation was also significantly reduced at visit 4 compared to baseline (P < 0,001), Overall, the total points reduced from median of 2 at baseline to 0 at visit 4; and the reduction was statistically significant (P < 0.001) (fig 2).
[Para0053] The gingivitis Criteria compared between baseline and visit 4 didnt show any statistical significance due to a fairly constant reponse at visit 3 and vsit 4 (Table 3).
[Para0054] Table 3: Comparison of gingivitis criteria before and after treatment
[ParaOQ55] Safety Results
[Para0056] There were insignificant changes in the parameters like systolic BP, diastolic BP, pulse rate, heart rate, respiratory rate and BMI between two times. There were no abnormal laboratory values reported during the study and no significant change in haematology. There was no change in vital parameters as compared to baseline. None of the patient experienced AEs during the study period in both canker sore and gingivitis atm. Thus, the tetrahydrocurcuminoids composition was acceptable in the study population and demonstrated as a completely safe preparation.
[Para0057] Example 3: Compositions / formulations containing tetrahydrocurcuminoids
[Para0058] Tables 4-9 provide illustrative examples of nutraceutical formulations containing tetrahydrocurcuminoids for the management of canker sore and gingivitis
[Para0059] Table 4: Tetrahydrocurcuminoids Chewable Tablet
[Para0062] Table 7; Tetrahydrocurcuminoids Tablet
[Para0065] Table 10 and 11 provides illustrative examples for a mouth gel and mouth wash formulation containing tetrahydrocurcuminoids for the management of canker sore and gingivitis
[Para0066] Table 10: Tetrahydrocurcuminoids mouth gel
[Para0070] Oral Health Kit
The invention also provides an illustrative example of an oral health kit comprising of formulation containing tetrahydracurcuminoids which include, but not limited to, the following:
1. Chewable tablets, candies and guinmies
2. Tablets and capsules containing tetrahydrocurcuminoids
3. Creams, lotions, ointments, gels containing tetrahydrocurcuminoids
4. Mouth wash and toothpaste
[ParaQ071] The above formulations are just illustrative examples, any formulation containing the above active ingredient intended for the said purpose will be considered equivalent.
[Para0072] Other modifications and variations to the invention will be apparent to those skilled in die art from the foregoing disclosure and teachings. Thus, while only certain embodiments of the invention have been specifically described herein, it will be apparent that numerous modifications may be made thereto without departing from the spirit and scope of the invention.
Claims
1. A composition containing tetrahydrocurcuntinoids for the improvement of oral health and hygiene.
2. The composition as in claim 1, wherein the composition is formuiated with pharmaceutically, nutraceutically and cosmeceutical!y acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders* suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
3. The formulation as in claim 2, wherein the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash tooth paste and eatables, are available separately or together in an oral health kit containing the said forms.
4. A method for therapeutic management of canker sore in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrahydrocurcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with canker sore.
5. The method as in claim 4, wherein the symptoms of canker sore include, but not limited to, throat pain, ulcer, lesion, throat numbness, sore throat, bleeding, swelling at the site, reddening at die site, inflammation at the site, burning , swelling and pain in lymph node, difficulty in chewing and difficulty in swallowing.
6. The method as in claim 4, wherein the composition is formulated with pharmaceutically, nutraceutically and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gummies, powders,
suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
7. The formulation as in claim 6, wherein the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash tooth paste and eatables, are available separately or together in an oral health kit containing the said forms.
8. The method as in claim 4, wherein the mammal is preferably human.
9. A method for therapeutic management of gingivitis in mammals, said method comprising steps of administering an effective concentration of a composition containing tetrabydrocorcuminoids to mammals in need of such therapy, to bring about reduction in symptoms associated with gingivitis.
10. The method as in claim 9, wherein the symptoms of gingivitis include, but not limited to, taste acceptability, burning sensation, dryness, soreness, ulcer, staining of teeth and tongue, and allergy.
11. The method as in claim 9, wherein the composition is formulated with pharmaceutically, nutracenticaliy and cosmeceutically acceptable excipients, adjuvants, diluents or carriers and administered in the form of tablets, capsules, syrups, gtunmies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables.
12. The formulation as in claim 11 , wherein the tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies, creams, gels, lotions, ointments, mouth wash, tooth paste and eatables, are available separately or together in a oral health kit containing the said forms.
13. The method as in claim 9, wherein the mammal is preferably human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/028077 WO2019203813A1 (en) | 2018-04-18 | 2018-04-18 | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/028077 WO2019203813A1 (en) | 2018-04-18 | 2018-04-18 | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019203813A1 true WO2019203813A1 (en) | 2019-10-24 |
Family
ID=68239733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/028077 WO2019203813A1 (en) | 2018-04-18 | 2018-04-18 | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019203813A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100034757A1 (en) * | 2006-11-24 | 2010-02-11 | Mitsukiyo Fujii | Extract powder of indigo plant, and its preparation and uses |
| US8182843B2 (en) * | 2006-06-30 | 2012-05-22 | Piramal Life Sciences Limited | Herbal compositions for the treatment of diseases of the oral cavity |
| US20140275271A1 (en) * | 2011-10-17 | 2014-09-18 | The Research Foundation For The State University Of New York | Novel modified curcumins and their uses |
| US8916139B2 (en) * | 2010-04-09 | 2014-12-23 | Conopco, Inc. | Oral care compositions |
| US20170319642A1 (en) * | 2014-10-27 | 2017-11-09 | Fbm Indústria Farmacêutica Ltda. | Soluble, stable, anti-inflammatory, proliferative, protective and mucoadhesive pharmaceutical compositions; use thereof for treating mucositis conditions and method for producing same; base pharmaceutical composition for preparing the pharmaceutical compositions and method for producing same |
-
2018
- 2018-04-18 WO PCT/US2018/028077 patent/WO2019203813A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8182843B2 (en) * | 2006-06-30 | 2012-05-22 | Piramal Life Sciences Limited | Herbal compositions for the treatment of diseases of the oral cavity |
| US20100034757A1 (en) * | 2006-11-24 | 2010-02-11 | Mitsukiyo Fujii | Extract powder of indigo plant, and its preparation and uses |
| US8916139B2 (en) * | 2010-04-09 | 2014-12-23 | Conopco, Inc. | Oral care compositions |
| US20140275271A1 (en) * | 2011-10-17 | 2014-09-18 | The Research Foundation For The State University Of New York | Novel modified curcumins and their uses |
| US20170319642A1 (en) * | 2014-10-27 | 2017-11-09 | Fbm Indústria Farmacêutica Ltda. | Soluble, stable, anti-inflammatory, proliferative, protective and mucoadhesive pharmaceutical compositions; use thereof for treating mucositis conditions and method for producing same; base pharmaceutical composition for preparing the pharmaceutical compositions and method for producing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pai et al. | Evaluation of antiplaque activity of Azadirachta indica leaf extract gel—a 6-week clinical study | |
| Parashar | Mouthwashes and their use in different oral conditions | |
| Deutsch et al. | Optimising oral health in frail older people | |
| Milligan et al. | Oral care for people with advanced cancer: an evidence-based protocol | |
| Perez-Nicolas et al. | Use and efficacy of mouthwashes in elderly patients: A systematic review of randomized clinical trials | |
| JP2009513492A (en) | Use of hyaluronic acid to produce a composition for the treatment of oral after | |
| Prakash et al. | Effect of punica granatum extract gel on gingival crevicular fluid levels of interleukin-1β, interleukin-8 and CCL28 levels: randomised controlled clinical trial | |
| Roopa et al. | Curcumin: a herbal approach in the management of gingivitis | |
| Thakare et al. | Genetic Mapping in Papillon‐Lefèvre Syndrome: A Report of Two Cases | |
| US20190321308A1 (en) | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene | |
| WO2019203813A1 (en) | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene | |
| WO2022200887A1 (en) | Natural multifunction coenzyme q10 liquid oral hygiene care with antimicrobial efficacy | |
| Van Zyl et al. | Mouthwash: a review for South African health care workers: CPD | |
| Goh et al. | Clinical assessment of a pharmaceutical polyphenol fruit extract gel to inhibit dental plaque | |
| RU2605260C1 (en) | Method of integrated treatment of patients with inflammatory periodontal diseases | |
| Sulaksana et al. | Oral mucosal burn caused by the topical application of a clove oil concentrate | |
| Gibson | Identifying and treating xerostomia in restorative patients | |
| Garg et al. | Merits of oil pulling therapy in the management of xerostomia and stomatopyrosis in burning mouth syndrome | |
| Singh et al. | Oral infections, a mirror of our overall health condition: An overview. | |
| Schmidt | Mouthwashes and gargles: oral health | |
| Rajesh et al. | Effectiveness of chlorhexidine gel and ozonated oil in treatment of plaque induced gingivitis–a randomized controlled clinical study | |
| Reduan et al. | Effects of a Stingless Bee Honey Mouth Rinse on Dental Plaque Accumulation: A Randomised Clinical Trial | |
| Kanika | Efficacious Evaluation of Aloe Vera Tooth Gel and Commercially Available Tooth Gel on Patients with Gingivitis | |
| Lewis et al. | Oral Ulceration | |
| SHIN et al. | 15 Gingivitis and Periodontal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18915043 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18915043 Country of ref document: EP Kind code of ref document: A1 |